Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Flagrante Delictu who wrote (19283)	4/18/1998 12:51:00 AM
From: bluejeans	Read Replies (1) \| Respond to of 32384

Bernie, Those Red Herring articles I posted the link on have some discussion about VC funding. Bob

To: Flagrante Delictu who wrote (19283)	4/18/1998 2:13:00 AM
From: WTDEC	Respond to of 32384

Bernie, >> "new drugs" rather than old drugs, which would appear more vulnerable>> is something I can completely agree with. Either the vc's presumed or I interpreted that they presumed the old drugs are already 'dead meat'. I think the big pharmas trade where they do because of their position and power from a financial standpoint (they can buy up biotechs as needed to protect their core positions), their marketing clout, current cash flow and low cost of capital, wide analyst coverage, part of the S&P index fund, inertia of institutional investors, etc., etc. I do think there is some feeling that new drug discovery technology is going to give the big guys some advantage because it will bring an order and discipline which they were not able to do on their own. I'm skeptical on this point, but it is worth keeping in mind. I propose we talk more about this ..see PM. Walter